Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with major morbidity, and after decades of slow progress it has entered a genuinely active therapeutic era — including a new approval for lupus nephritis and the most dramatic cell-therapy results seen in any autoimmune condition.
Type I interferon blockade: anifrolumab
Anifrolumab, a monoclonal antibody against the type I interferon receptor, produced significantly higher response rates than placebo at 52 weeks in its pivotal TULIP-2 trial (47.8% vs 31.5%), at the cost of more herpes zoster and respiratory infections. It is now approved for moderate-to-severe SLE, particularly in patients not controlled on standard therapy.
B-cell depletion for lupus nephritis: obinutuzumab (now approved)
Obinutuzumab, a type II anti-CD20 antibody with enhanced B-cell cytotoxicity, followed its Phase 2 NOBILITY signal with the pivotal Phase 3 REGENCY trial, in which adding obinutuzumab to standard therapy significantly increased complete renal response at 76 weeks (46.4% vs 33.1%), alongside improvements in complement, anti-dsDNA, proteinuria, and steroid use. On this basis, obinutuzumab was FDA-approved for active lupus nephritis in October 2025 — a meaningful addition to the B-cell-directed armamentarium, given with an initial loading schedule followed by twice-yearly dosing. It joins belimumab (a BAFF inhibitor and the first biologic approved for lupus nephritis, now a first-line option for proliferative disease in the 2024 KDIGO guidelines) as validated B-cell-pathway therapy in nephritis.
Other targeted and cell-based approaches
Litifilimab (anti-BDCA2), which dampens plasmacytoid dendritic cell interferon production, reduced joint counts in Phase 2 and is advancing through later trials. Low-dose interleukin-2, which selectively expands regulatory T cells, has shown encouraging response rates in early studies and remains investigational. The pipeline also includes dapirolizumab pegol (an anti-CD40L agent with a positive Phase 3 in SLE) and deucravacitinib (an oral TYK2 inhibitor).
The headline experimental advance is CD19 CAR-T cell therapy: in refractory SLE it has produced durable, drug-free remission — among the most compelling results in the whole autoimmune CAR-T field, with lupus showing the lowest relapse rates of the diseases treated. The evidence is still limited to small, uncontrolled case series with 1–2 year follow-up, and cost and safety questions remain, but it points toward the possibility of resetting rather than suppressing lupus autoimmunity.
| Therapy | Target | Key result | Status |
|---|---|---|---|
| Anifrolumab | Type I IFN receptor | TULIP-2 response 47.8% vs 31.5% | Approved (moderate-severe SLE) |
| Obinutuzumab | CD20 (type II) | REGENCY renal response 46.4% vs 33.1% | Approved for lupus nephritis (2025) |
| Belimumab | BAFF | Improved renal response, fewer flares | First-line for proliferative LN (KDIGO 2024) |
| Litifilimab | BDCA2 / pDC | Reduced joint counts (Phase 2) | In later-phase trials |
| CD19 CAR-T | B-cell depletion | Durable drug-free remission | Experimental; small series |
Further reading: TULIP-2 anifrolumab (Morand et al., NEJM 2020); REGENCY obinutuzumab (Furie et al., NEJM 2025) and FDA approval (2025); litifilimab (Furie et al., NEJM 2022); CAR-T in autoimmune disease (Müller et al., NEJM 2024).